Although antidepressants may not be primary mood stabilizers, they are efficacious in the prophylaxis of recurrent depressive illnesses, as well as in the treatment of acute episodes. Pharmacological effects that may contribute to the prophylactic effects of these drugs are not understood. Studies have been carried out in which antidepressants have been given to laboratory animals, such as rats, for periods of up to 3-4 weeks. Data obtained in such studies are thought to be important for their beneficial effects in depressive episodes, but also may be relevant to their prophylactic effects. Results are presented showing that when selective inhibitors of serotonin or norepinephrine uptake are given for such time periods, they still produce selective effects on serotonergic or noradrenergic parameters. For example, longterm administration of selective norepinephrine reuptake inhibitors causes a down-regulation of ␤ 1 adrenoceptors. Selective serotonin reuptake inhibitors do not produce this effect. Longterm administration of selective serotonin reuptake inhibitors causes down-regulation of the serotonin transporter, but not the norepinephrine transporter. In contrast, selective norepinephrine reuptake inhibitors down-regulate the norepinephrine transporter but not the serotonin transporter. Substantial loss of serotonin transporter binding sites takes 15 days to occur and is accompanied by a marked reduction of serotonin transporter function in vivo. Molecular Psychiatry (2002) 7, S23-S28.
Introduction
It may be viewed as inappropriate to discuss antidepressants in a symposium devoted to drugs that are primary mood stabilizers. This is because the prototypical mood stabilizer, the lithium ion, has been known for many years to be effective in acute mania, as well as the prophylaxis of recurrent episodes of mania or depression. In contrast, most early research of depression emphasized single episodes and their treatment. However, in the last 20 years, the recurrent nature of unipolar depression became evident and established, 1, 2 as did the fact that all types of antidepressants were efficacious prophylactic agents for this disorder. 3 Thus, drug treatment for over 50% of patients with major depressive disorder can extend for many years, so as to decrease the probability and intensity of recurrences.
In spite of this realization, there has been a virtual absence of study of the pharmacological effects of antidepressants that may be responsible for such prophylactic effects. This may be, in part, because of the lack of animal models for the recurrent nature of major depressive illness, with the emphasis of most such research being on the development of models exhibitCorrespondence: Dr A Frazer, Department of Pharmacology, UTHSCSA, Mail Code 7764, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA ing symptoms that resemble the syndrome of major depression. 4, 5 Similarly, there have been no views put forward as to the time course of pharmacological effects involved in prophylaxis-must such effects not occur for months, or longer? If so, they would be quite distinct from those thought to be involved in recovery from a depressive episode. Shown in Figure 1 are possible time courses for clinical improvement of an acute depressive episode. It is widely believed that the 'onset' of beneficial drug effects in depression is delayed for 2 or 3 weeks, 6, 7 shown by the line labeled 'lag.' This view has been challenged recently, 8, 9 leading to the idea that not only can 'early' improvement be detected in eventual drug responders, but also that the absence of such early improvement predicts poor clinical response. This view is indicated by the line labeled 'linear' in Figure  1 . Regardless of which view prevails, there is consensus that maximal or optimal drug-induced improvement of depression is slow, taking 6-12 weeks to occur. We do not yet have an 'ideal' drug ( Figure 1 ) that produces rapid, optimal recovery from depression. Realization that optimal recovery was slow stimulated research into pharmacological effects of antidepressants that began in only 1-3 weeks. The idea behind these studies was that either such delayed effects actually initiated recovery, consistent with the 'lag' viewpoint, or permitted initial improvement to proceed to a fuller response (the 'linear' view). Response is indicated as Ն50% decrease in the baseline HAM-D score, whereas recovery is defined as not only Ն50% decrease but a final HAM-D score Յ7. Indicated in the figure is the idea that available antidepressants do not produce their maximal beneficial effects for 6 weeks.
By characterizing such delayed effects, it was hoped that drugs could be developed that elicited them much more quickly, thereby producing an optimal response more rapidly. Many delayed pharmacological effects of antidepressants have been identified [10] [11] [12] and have been speculated to be important in the recovery process from acute depression. Again, whether these delayed effects are involved in the prophylactic effects of these drugs is not only unknown, but does not even appear to have been considered. It would seem useful to begin to evaluate if the actions of antidepressants on synaptic physiology that produce intracellular effects that result in neuroplastic changes may be involved in the prophylactic effects of these drugs.
It seems clear that the cascade of delayed pharmacological effects is triggered by their acute effects, usually on noradrenergic and/or serotonergic neurons. 13 What might be useful, then, is to review some delayed effects we have found of antidepressants on central noradrenergic or serotonergic neuronal systems. Our results, in general, show that drugs that affect selectively noradrenergic neurons acutely, cause selective effects on such neurons when given chronically, ie, selective noradrenergic reuptake inhibitors (NRIs) do not produce effects on serotonergic systems. Similarly, repeated administration of selective serotonin reuptake inhibitors (SSRIs) affect serotonergic, but not noradrenergic, parameters. Such long-term selectivity in animals is consistent with clinical studies indicating that selective reuptake inhibitors cause efficacy through different biogenic amine systems. 14, 15 
Delayed pharmacological effects of antidepressants
Effects on beta 1 adrenoceptors An early, and now well-established, long-term effect of certain antidepressants is the development of ␤ 1 -adrenoceptor subsensitivity due to the down-regulation of these receptors. 12, 16, 17 We have found that those antidepressants that cause this effect do so most robustly in certain amygdaloidal nuclei, such as its basolateral nucleus. 18 Moreover, down-regulation of ␤ 1 adrenoceptors is only produced by drugs that acutely enhance noradrenergic function; SSRIs, for example, do not produce this effect ( Figure 2 ). 18 This inability of SSRIs was taken by some to mean that ␤ 1 -adrenoceptor down-regulation was not important for antidepressant efficacy. The assumption behind this view is that all antidepressants must work the same way. There are little data to support such an assumption and, as mentioned, clinical data that are inconsistent with it.
14,15 The down-regulation of the ␤ 1 -adrenoceptor may be an important component of the mechanism of action of those antidepressants that produce it, perhaps leading to a decrease in noradrenergic transmission in areas of brain such as the hippocampus. 12 As indicated earlier, however, it is unknown if this pharmacological effect has any relevance for the prophylactic effect of antidepressants.
Effects on serotonergic transporters
Much less research has been carried out investigating regulatory effects of antidepressants on the transporters for 5-HT or norepinephrine than on receptors for these biogenic amines, yet these plasma membrane transporters are the initial cellular targets for the great 
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Delayed pharmacological effects of antidepressants A Frazer and S Benmansour S25 majority of antidepressants. 19 Further, studies carried out in vitro during the last decade demonstrated conclusively that these transporters exhibit plasticity. 20 However, the literature on the effects of long-term antidepressants on the serotonin transporter (SERT) or norepinephrine transporter (NET) are inconsistent. [21] [22] [23] [24] [25] [26] [27] We decided to re-examine this issue, and speculated that two factors needed to be addressed in our studies. One was how the drugs are administered. It seemed that sustained high occupancy of these transporters by the reuptake inhibitors might be required for regulatory effects to occur. Although such occupancy is likely to happen when these drugs are used clinically, this may not be so when the drugs are given in the usual way, ie, once or twice daily, to rats. This is because the metabolism of drugs is faster in rats than it is in humans. Most uptake inhibitors (or their active metabolites) have half-lives in humans that average about 1 day or even longer. 28 Given this, even administration once per day with doses producing recommended serum concentrations (usually measured at the trough of the daily variation in concentration) is sufficient to maintain consistent blockade of the transporter. A calculation may be useful to show this. Therapeutic serum concentrations of sertraline are 30-150 ng ml −1 . The low value of 30 ng ml −1 is equivalent to about 100 nM. Even if 99% of sertraline is protein bound, 28 it should be present in the extracellular fluid in brain at a concentration of 1 nM. The K i value of sertraline to bind to the hSERT is ෂ0.15-0.3 nM. 29 Thus, in humans, the minimum concentration of sertraline found during the day should still occupy no less than 77% of SERT binding sites. In contrast, sertraline has a half-life of ෂ4.5 h in rats. 30 Thus, twice-daily, but especially once-daily, injections of this drug may not be sufficient to maintain adequate occupancy of the SERT in brain throughout the day, and continuous adequate occupancy may be necessary to obtain regulatory effects. Such considerations are equally important with a drug such as citalopram, which has an elimination half-life in the rat of 3-5 h, 31 or venlafaxine or its metabolite o-desmethylvenlafaxine with half-lives of ෂ1 h. 32 Consequently, in our studies 33, 34 the uptake inhibitors were given by osmotic minipump so as to achieve stable serum concentrations throughout the day. Furthermore, doses were adjusted to achieve serum concentrations in the 'therapeutic' range. Finally, after giving the drugs for various time periods, experiments were carried out only after allowing time for the drugs to wash out of the body (ie, serum concentrations Ͻ5 ng ml ), so as to make certain that effects observed were not due to physical presence of the drug.
The second factor that was addressed was utilization of a technique that assessed SERT function in vivo. In general, previous studies used parameters that either do not measure SERT function (eg, ligand binding, mRNA for the SERT) or measure function in vitro (uptake into brain slices or synaptosomes). Although a useful measure, factors that might contribute to regulatory effects may be lost during tissue preparation or Molecular Psychiatry by the use of artificial incubation media. Consequently, we adopted the technique of chronoamperometry to measure the clearance of exogenous 5-HT locally applied into the CA 3 region of the hippocampus of anesthetized rats. 35, 36 Chronoamperometry is a specific type of voltametric technique. For voltametry, a small potential is applied to an electrode and the current that results from oxidation (and subsequent reduction) of electroactive species near the electrode surface is measured. In chronoamperometry, voltage is applied to the electrode in a 'pulsed' or 'stepped' manner and the current generated measured as a function of time.
Advantages of chronoamperometry are its spatial resolution (the diameter of the carbon fiber electrode used is 30 m, which is much smaller than that of most dialysis probes, ie, 300-500 m) and temporal resolution (with measurements taken over an 80-ms time frame compared with the 5-to 20-min time intervals used for dialysis). Disadvantages of chronoamperometry are that it is not sufficiently sensitive to measure basal levels of 5-HT in the extracellular fluid and there can be problems identifying the chemicals contributing to the electrochemical signals generated. 37 Because of these limitations, our approach has been to pressureeject very small amounts of 5-HT into the vicinity of the recording electrode in the hippocampus and measure the signal produced due to 5-HT. When this is done, a signal is produced, such as that shown in Figure 3 .
The greater the concentration of 5-HT oxidized at the electrode tip, the larger the electrochemical signal generated. Thus, the signal reaches some peak amplitude, dependent on the amount of 5-HT administered, and then declines over time as the 5-HT clears away from Figure 3 Pressure ejection of 5-HT (10 pmoles) produces an electrochemical signal characterized by a peak amplitude of about 0.7 M. Over time, the concentration of 5-HT at the electrochemical detector is reduced, such that no signal is detected after ෂ3 min. Local application of fluvoxamine about 90 s prior to a subsequent injection of 5-HT inhibits the rate of clearance of 5-HT, although having no effect on peak amplitude.
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Molecular Psychiatry the electrode tip. This 'clearance' of 5-HT is due both to diffusion and to the reuptake of 5-HT by the SERT. This latter component can be measured by locally applying SSRIs, such as fluvoxamine, prior to administration of 5-HT. When this is done (Figure 3) , there is little effect on the amplitude of the signal, but the rate of clearance is decreased. Various parameters can be calculated from the clearance curve, such as the time it takes for the peak signal to be decreased in amplitude by 80%, the t 80 value. SSRIs consistently increase the t 80 value, by ෂ30-40% (Figure 3) . Therefore, the clearance curve of exogenously administered 5-HT provides an index of SERT activity in vivo. Treatment of rats for 3 weeks with SSRIs, but not the selective NRI, desipramine, or the monoamine oxidase inhibitor, phenelzine, diminished SERT function in vivo. 33 This was shown primarily by the inability of fluvoxamine to prolong the clearance of 5-HT in rats treated with the SSRIs. In contrast, in rats treated with either desipramine or phenelzine, fluvoxamine was still able to increase the t 80 value (see Table 1 ).
This decreased function of the SERT was accompanied by a marked loss of binding sites for the SERT throughout brain, as revealed by measuring the binding of 3 H-cyanoimipramine ( 3 H-CN-IMI) by quantitative autoradiography. 33 After 3 weeks of treatment with paroxetine or sertraline, ligand binding was reduced by Ն80%, whereas neither desipramine or phenelzine treatment decreased the binding.
Recently, we have examined the time course for the decrease in binding of 3 H-CN-IMI on treatment of rats with sertraline (7.5 mg kg
by osmotic minipump) for 4, 10, 15 or 21 days, always followed by a 2-day washout. As shown in Table 2 , binding of 3 H-CN-IMI only decreased marginally over the first 10 days of treatment. However, after 15 days of treatment, binding was reduced by Ͼ85% and this effect persisted at 21 days of treatment. This time course for the reduction of binding was interesting from the perspective of clinical improvement. We speculated that the time-dependent decrease in binding of the SERT may cause markedly diminished SERT function in vivo, and only when this occurs is there marked enhancement of serotonergic transmission, with consequent behavioral improvement in patients. In our previous study, 33 diminished functioning of the SERT was inferred after 21 days of treatment with SSRIs by the inability of acute fluvoxamine to prolong the clearance of exogenous 5-HT, as measured by chronoamperometry. Little attention was paid to the effect of the treatments on the actual electrochemical signal produced by 5-HT. We have recently studied this in rats treated with sertraline for 4, 10 or 15 days. Our hypothesis was that only when SERT binding sites are markedly reduced, ie, after 15 days of treatment, would there be robust alterations in the 5-HT electrochemical signal.
We have now shown this. The signal produced by administration of three amounts of 5-HT (5, 10 or 15 pmoles) into the CA 3 region of each rat, was measured. The signals were comparable in rats treated for 4 or 10 days with sertraline to those measured in rats given vehicle. No statistically significant increases were seen either in the peak amplitude of the signals produced by these amounts of 5-HT or the time course of clearance for 5-HT. By contrast, in rats treated with sertraline for 15 days, the 5-HT signal was augmented markedly. Shown, for example, in Table 3 , are the amplitudes and t 80 values for the 5-HT signal generated by 10.4 pmoles of 5-HT in control rats or those rats given sertraline for 15 days. 
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It is of interest that this marked sertraline-induced enhancement of the 5-HT signal is not seen either earlier in treatment or following acute local administration of an SSRI (Figure 3 ). It appears that the loss of transporter produces much greater change in the 5-HT electrochemical signal than that seen on competitive blockade of the SERT with an SSRI. Why this is so is unclear and deserves further study. However, if the effects measured using chronoamperometry mimic what is happening to actual serotonergic neurotransmission, it would seem that SSRIs cause only a modest increase of transmission early in treatment. It is when these drugs cause a loss of SERT binding sites that there would be marked enhancement of transmission. Thus, the loss of binding sites may be very important in further increasing the initial modest increase in transmission that occurs on acute blockade of uptake. If so, understanding the mechanisms leading to SERT down-regulation may permit the development of drugs that produce this effect more quickly, permitting perhaps more rapid clinical improvement.
Noradrenergic transporters
Finally, because of our results on the effects of chronic administration of SSRIs on the SERT, we decided to see if selective NRIs, such as desipramine, would down-regulate the norepinephrine transporter. Consequently, binding of the radioligand 3 H-nisoxetine to the norepinephrine transporter 38 was measured in the same rats treated for 21 days with either paroxetine or desipramine, in which 3 H-CN-IMI binding had been ). The rats were killed by decapitation either 3 days after desipramine was stopped or after 4 days for paroxetine. Binding of the radioligand 3 H-nisoxetine to the NET was assessed in different areas of brain using quantitative autoradiography. 38 In areas such as the basolateral nucleus of the amygdala (BLA) or CA 3 region, rats treated with desipramine showed a significant decrease in binding (P Ͻ 0.001). By contrast, paroxetine treatment had no effect on this parameter.
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measured. 33 Shown in Figure 4 , for example, are results obtained in the basolateral nucleus of the amygdala and the CA 3 region of the hippocampus. Treatment with desipramine reduced the binding of 3 H-nisoxetine to the norepinephrine transporter throughout brain. By contrast, treatment with paroxetine was without effect. We have obtained results with reboxetine, a new selective NRI, that are quite similar to those seen with desipramine (unpublished data).
Thus, these results are consistent with the idea that drugs with selectivity for the SERT or norepinephrine transporter in vitro, or acutely in vivo, produce selective effects on these neuronal systems when given chronically. Chronic administration of SSRIs downregulate SERTs but not norepinephrine transporter, whereas selective NRIs cause the opposite effect. Transporter down-regulation would appear to be a useful end point to assess in vivo the long-term effects of antidepressants on SERT and norepinephrine transporter functioning. However, whether those pharmacological effects are relevant to the prophylactic effects of reuptake inhibitors in recurrent depression remains unknown.
